A detailed history of Brevan Howard Capital Management LP transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 4,595 shares of CRSP stock, worth $233,609. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,595
Holding current value
$233,609
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$44.62 - $62.75 $205,028 - $288,336
4,595 New
4,595 $215,000
Q4 2023

Feb 14, 2024

BUY
$38.62 - $72.18 $224,459 - $419,510
5,812 New
5,812 $363,000
Q2 2021

Aug 13, 2021

SELL
$100.84 - $161.89 $1.5 Million - $2.41 Million
-14,911 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$110.72 - $210.04 $917,758 - $1.74 Million
-8,289 Reduced 35.73%
14,911 $1.82 Million
Q4 2020

Feb 12, 2021

BUY
$79.67 - $173.23 $1.85 Million - $4.02 Million
23,200 New
23,200 $3.55 Million

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.97B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Brevan Howard Capital Management LP Portfolio

Follow Brevan Howard Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brevan Howard Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Brevan Howard Capital Management LP with notifications on news.